Comparable graft survival is achievable with the usage of donation after circulatory death liver grafts from donors at or above 70 years of age: A long-term UK national analysis.

clinical research/practice donors and donation: donation after circulatory death (DCD) donors and donation: extended criteria liver transplantation/hepatology organ acceptance organ allocation organ procurement organ procurement and allocation

Journal

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638

Informations de publication

Date de publication:
06 2021
Historique:
revised: 06 11 2020
received: 05 03 2020
accepted: 13 11 2020
pubmed: 23 11 2020
medline: 29 6 2021
entrez: 22 11 2020
Statut: ppublish

Résumé

The aim of the study was to assess the UK donation after circulatory death (DCD) liver transplant experience from donors ≥70 years. Nationwide UK DCD retrospective analysis was conducted between 2001 and 2015 (n = 1163). Recipients were divided into group 1 vs. group 2 (donors 70≥ vs. <70 years, respectively). group 1 (n = 69, 5.9%) recipients were older (median 59 vs. 55 years, p = .001) and had longer waitlist time (128 vs. 84 days; p = .039). 94.2% of group 1 clustered in London and Birmingham, where the two busiest centers are located. group 1 allografts had higher UKDRI and UK DCD Risk Scores but similar WIT and CIT and were more likely to have been imported. Both groups had similar 1-, 3-, and 5-year graft survival (group 1, 90%, 81.4%, and 74% vs. group 2, 88.6%, 81.4%, and 78.6%, respectively; p = .54). Both groups had similar ICU stay length (p = .22), 3-month hepatic artery thrombosis rates (4.4% vs 4.0%; p = .9), and 12-month readmission rates for all biliary complications (20.3% vs 25.7%; p = .32). This study demonstrates that acceptable outcomes are achievable using older grafts in a highly selected cohort at experienced centers. Advanced age should not be an absolute contraindication to utilizing a DCD graft from donors aged ≥70 years.

Identifiants

pubmed: 33222386
doi: 10.1111/ajt.16409
pii: S1600-6135(22)08594-X
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2200-2210

Informations de copyright

© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.

Références

Washburn K, Pomfret E, Roberts J. Liver allocation and distribution: possible next steps. Liver Transpl. 2011;17(9):1005-1012. https://doi.org/10.1002/lt.22349
Foley DP, Fernandez LA, Leverson G, et al. Donation after cardiac death: the University of Wisconsin experience with liver transplantation. Ann Surg. 2005;242(5):724-731. https://doi.org/10.1097/01.sla.0000186178.07110.92
Mateo R, Cho Y, Singh G, et al. Risk factors for graft survival after liver transplantation from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant. 2006;6(4):791-796. https://doi.org/10.1111/j.1600-6143.2006.01243.x
de Vera ME, Lopez-Solis R, Dvorchik I, et al. Liver transplantation using donation after cardiac death donors: long-term follow-up from a single center. Am J Transplant. 2009;9(4):773-781. https://doi.org/10.1111/j.1600-6143.2009.02560.x
Croome KP, Lee DD, Keaveny AP, Taner CB. Improving National Results in Liver Transplantation Using Grafts From Donation After Cardiac Death Donors. Transplantation. 2016;100(12):2640-2647. https://doi.org/10.1097/tp.0000000000001483
Croome KP, Lee DD, Perry DK, et al. Comparison of longterm outcomes and quality of life in recipients of donation after cardiac death liver grafts with a propensity-matched cohort. Liver Transpl. 2017;23(3):342-351. https://doi.org/10.1002/lt.24713
Laing RW, Scalera I, Isaac J, et al. Liver Transplantation Using Grafts From Donors After Circulatory Death: A Propensity Score-Matched Study From a Single Center. Am J Transplant. 2016;16(6):1795-1804. https://doi.org/10.1111/ajt.13699
Firl DJ, Hashimoto K, O'Rourke C, et al. Impact of donor age in liver transplantation from donation after circulatory death donors: A decade of experience at Cleveland Clinic. Liver Transpl. 2015;21(12):1494-1503. https://doi.org/10.1002/lt.24316
Harring TR, Nguyen NTT, Cotton RT, et al. Liver transplantation with donation after cardiac death donors: a comprehensive update. J Surg Res. 2012;178(1):502-511. https://doi.org/10.1016/j.jss.2012.04.044
Mathur AK, Heimbach J, Steffick DE, Sonnenday CJ, Goodrich NP, Merion RM. Donation after cardiac death liver transplantation: predictors of outcome. Am J Transplant. 2010;10(11):2512-2519. https://doi.org/10.1111/j.1600-6143.2010.03293.x
Detry O, Donckier V, Lucidi V, et al. Liver transplantation from donation after cardiac death donors: initial Belgian experience 2003-2007. Transpl Int. 2010;23(6):611-618. https://doi.org/10.1111/j.1432-2277.2009.01029.x
Cascales-Campos PA, Ferreras D, Alconchel F, et al. Controlled donation after circulatory death up to 80 years for liver transplantation: Pushing the limit again. Am J Transplant. 2020;20(1):204-212. https://doi.org/10.1111/ajt.15537
Croome KP, Mathur AK, Lee DD, et al. Outcomes of Donation After Circulatory Death Liver Grafts From Donors 50 Years or Older: A Multicenter Analysis. Transplantation. 2018;102(7):1108-1114. https://doi.org/10.1097/tp.0000000000002120
Schlegel A, Scalera I, Perera MTPR, et al. Impact of donor age in donation after circulatory death liver transplantation: Is the cutoff "60" still of relevance? Liver Transpl. 2018;24(3):352-362. https://doi.org/10.1002/lt.24865
Melcher M. UK DCD Risk Calculator.
Schlegel A, Kalisvaart M, Scalera I, et al. The UK DCD Risk Score: A new proposal to define futility in donation-after-circulatory-death liver transplantation. J Hepatol. 2018;68(3):456-464. https://doi.org/10.1016/j.jhep.2017.10.034
Collett D, Friend PJ, Watson CJ. Factors Associated With Short- and Long-term Liver Graft Survival in the United Kingdom: Development of a UK Donor Liver Index. Transplantation. 2017;101(4):786-792. https://doi.org/10.1097/tp.0000000000001576
Khorsandi SE, Giorgakis E, Vilca-Melendez H, et al. Developing a donation after cardiac death risk index for adult and pediatric liver transplantation. World J Transplant. 2017;7(3):203-212. https://doi.org/10.5500/wjt.v7.i3.203
Farid SG, Attia MS, Vijayanand D, et al. Impact of Donor Hepatectomy Time During Organ Procurement in Donation After Circulatory Death Liver Transplantation: The United Kingdom Experience. Transplantation. 2019;103(4):e79-e88. https://doi.org/10.1097/tp.0000000000002518
NHSBT. ODT Policies And Reports. https://www.odt.nhs.uk/retrieval/policies-and-nors-reports/
Giorgakis E, Khorsandi SE, Jassem W, Heaton N. Minimization of ischemic cholangiopathy in donation after cardiac death liver transplantation: Is it thrombolytic therapy or warm ischemic time stringency and donor bile duct flush? Am J Transplant. 2018;18(1):274-275. https://doi.org/10.1111/ajt.14429
NHSBT. ODT CLINICAL Organ Specific Reports 2018-2019 reports. odt.nhs.uk/statistics-and-reports/organ-specific-reports/
Hibi T, Sapisochin G. What is transplant oncology? Surgery. 2019;165(2):281-285. https://doi.org/10.1016/j.surg.2018.10.024
Sapisochin G, Goldaracena N, Laurence JM, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology. 2016;64(6):2077-2088. https://doi.org/10.1002/hep.28643
Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016;64(4):1178-1188. https://doi.org/10.1002/hep.28744
Gorgen A, Muaddi H, Zhang W, McGilvray I, Gallinger S, Sapisochin G. The new era of transplant oncology: Liver transplantation for nonresectable colorectal cancer liver metastases. Can J Gastroenterol Hepatol. 2018;2018:9531925. https://doi.org/10.1155/2018/9531925
Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006;6(4):783-790. https://doi.org/10.1111/j.1600-6143.2006.01242.x
Hessheimer AJ, Cardenas A, Garcia-Valdecasas JC, Fondevila C. Can we prevent ischemic-type biliary lesions in donation after circulatory determination of death liver transplantation? Liver Transpl. 2016;22(7):1025-1033. https://doi.org/10.1002/lt.24460
Bohorquez H, Seal JB, Cohen AJ, et al. Safety and outcomes in 100 consecutive donation after circulatory death liver transplants using a protocol that includes thrombolytic therapy. Am J Transplant. 2017;17(8):2155-2164. https://doi.org/10.1111/ajt.14261
Nasralla D, Coussios CC, Mergental H, et al. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557(7703):50-56. https://doi.org/10.1038/s41586-018-0047-9
Weissenbacher A, Vrakas G, Nasralla D, Ceresa CDL. The future of organ perfusion and re-conditioning. Transpl Int. 2019;https://doi.org/10.1111/tri.13441
DeOliveira ML, Jassem W, Valente R, et al. Biliary complications after liver transplantation using grafts from donors after cardiac death: results from a matched control study in a single large volume center. Ann Surg. 2011;254(5):716-723. https://doi.org/10.1097/SLA.0b013e318235c572
Chapman WC, Vachharajani N, Collins KM, et al. Donor Age-Based Analysis of Liver Transplantation Outcomes: Short- and Long-Term Outcomes Are Similar Regardless of Donor Age. J Am Coll Surg. 2015;221(1):59-69. https://doi.org/10.1016/j.jamcollsurg.2015.01.061
Darius T, Monbaliu D, Jochmans I, et al. Septuagenarian and octogenarian donors provide excellent liver grafts for transplantation. Transplant Proc. 2012;44(9):2861-2867. https://doi.org/10.1016/j.transproceed.2012.09.076
Haugen CE, Bowring MG, Holscher CM, et al. Survival benefit of accepting livers from deceased donors over 70 years old. Am J Transplant. 2019;19(7):2020-2028. https://doi.org/10.1111/ajt.15250
Giorgakis E, Khorsandi SE, Jassem W, Heaton N. DCD consensus and futility in liver transplantation. J Hepatol. 2018;69(1):255-256. https://doi.org/10.1016/j.jhep.2018.03.032
Vining CC, Ecker BL, Abt PL, Olthoff KM. Donation after cardiac death in the hepatocellular carcinoma patient: Same indication? Liver Transpl. 2017;23(S1):S27-s33. https://doi.org/10.1002/lt.24862
Khorsandi SE, Yip VS, Cortes M, et al. Does donation after cardiac death utilization adversely affect hepatocellular cancer survival? Transplantation. 2016;100(9):1916-1924. https://doi.org/10.1097/tp.0000000000001150
Giorgakis E, Burdine L, Khorsandi S, Garcia MS, Heaton N, Mathur A. Impact of center volume on donation after circulatory death liver transplant outcomes. A retrospective scientific registry of transplant recipients analysis. Conference abstract. Transplantation. 8.1.2019 2019;103(8):30.
Hobeika MJ, Menser T, Nguyen DT, Beal LL, Zajac S, Graviss EA. United States donation after circulatory death liver transplantation is driven by a few high-utilization transplant centers. Am J Transplant. 2020;20(1):320-321. https://doi.org/10.1111/ajt.15629
Oniscu GC, Randle LV, Muiesan P, et al. In situ normothermic regional perfusion for controlled donation after circulatory death-the United Kingdom experience. Am J Transplant. 2014;14(12):2846-2854. https://doi.org/10.1111/ajt.12927

Auteurs

Emmanouil Giorgakis (E)

Department of Surgery, Division of Solid Organ Transplantation, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Shirin E Khorsandi (SE)

Institute of Liver Studies, King's College Hospital, London, UK.

Amit K Mathur (AK)

Department of Surgery, Division of Transplantation, Mayo Clinic, Phoenix, Arizona.

Lyle Burdine (L)

Department of Surgery, Division of Solid Organ Transplantation, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Wayel Jassem (W)

Institute of Liver Studies, King's College Hospital, London, UK.

Nigel Heaton (N)

Institute of Liver Studies, King's College Hospital, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH